

# Managing the challenge of chemically reactive metabolites

Nature Reviews Drug Discovery

10, 292-306

DOI: [10.1038/nrd3408](https://doi.org/10.1038/nrd3408)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A review of the use of <i>in silico</i> methods to predict the chemistry of molecular initiating events related to drug toxicity. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1481-1495.	1.5	34
2	2-Deoxyguanosine as a surrogate trapping agent for DNA reactive drug metabolites. Toxicology Letters, 2011, 207, 34-41.	0.4	5
3	2,7-Disubstituted-Pyrrolotriazine Kinase Inhibitors with an Unusually High Degree of Reactive Metabolite Formation. Chemical Research in Toxicology, 2011, 24, 1994-2003.	1.7	9
4	Predicting <i>in vivo</i> safety characteristics using physicochemical properties and <i>in vitro</i> assays. Future Medicinal Chemistry, 2011, 3, 1503-1511.	1.1	9
5	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: A novel histamine H4 receptor antagonist. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6596-6602.	1.0	32
6	Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States. Chemical Research in Toxicology, 2011, 24, 1345-1410.	1.7	569
7	The influence of the 'organizational factor' on compound quality in drug discovery. Nature Reviews Drug Discovery, 2011, 10, 749-765.	21.5	146
8	High-resolution chromatography/time-of-flight MS with <i>in silico</i> data mining is an information-rich approach to reactive metabolite screening. Rapid Communications in Mass Spectrometry, 2011, 25, 3029-3040.	0.7	46
9	Evaluation of the pharmacokinetics, biotransformation and hepatic transporter effects of troglitazone in mice with humanized livers. Xenobiotica, 2012, 42, 503-517.	0.5	32
10	Application of LC-high-resolution MS with intelligent data mining tools for screening reactive drug metabolites. Bioanalysis, 2012, 4, 501-510.	0.6	17
11	High-Resolution Mass Spectrometry Elucidates Metabolite (False Metabolite) Formation from Alkylamine Drugs during In Vitro Metabolite Profiling. Drug Metabolism and Disposition, 2012, 40, 1966-1975.	1.7	7
12	Animal models in an age of personalized medicine. Personalized Medicine, 2012, 9, 47-64.	0.8	25
13	Novel Bioactivation Mechanism of Reactive Metabolite Formation from Phenyl Methyl-Isoxazoles. Drug Metabolism and Disposition, 2012, 40, 2185-2191.	1.7	8
14	An Investigation of the Bioactivation Potential and Metabolism Profile of Zebrafish versus Human. Journal of Biomolecular Screening, 2012, 17, 974-986.	2.6	49
15	Characterization of THLE-Cytochrome P450 (P450) Cell Lines: Gene Expression Background and Relationship to P450-Enzyme Activity. Drug Metabolism and Disposition, 2012, 40, 2054-2058.	1.7	18
16	Ligand- and Protein-Based Modeling Studies of the Inhibitors of Human Cytochrome P450 2D6 and a Virtual Screening for Potential Inhibitors from the Chinese Herbal Medicine, Scutellaria baicalensis (Huangqin, Baikal Skullcap). Combinatorial Chemistry and High Throughput Screening, 2012, 15, 36-80.	0.6	20
21	Bioactivation of 2-(Alkylthio)-1,3,4-Thiadiazoles and 2-(Alkylthio)-1,3-Benzothiazoles. Chemical Research in Toxicology, 2012, 25, 2770-2779.	1.7	9
22	Systems biology tools for toxicology. Archives of Toxicology, 2012, 86, 1251-1271.	1.9	41

#	ARTICLE	IF	CITATIONS
23	Role of innate and adaptive immunity during drug-induced liver injury. <i>Toxicology Research</i> , 2012, 1, 161.	0.9	14
24	Drug-mediated toxicity: illuminating the “bad” in the test tube by means of cellular assays?. <i>Trends in Pharmacological Sciences</i> , 2012, 33, 353-364.	4.0	18
25	Metabolic Activation and Major Protein Target of a 1-Benzyl-3-carboxyazetidine Sphingosine-1-phosphate-1 Receptor Agonist. <i>Chemical Research in Toxicology</i> , 2012, 25, 1412-1422.	1.7	15
26	Bioactivation of Fluorinated 2-Aryl-benzothiazole Antitumor Molecules by Human Cytochrome P450s 1A1 and 2W1 and Deactivation by Cytochrome P450 2S1. <i>Chemical Research in Toxicology</i> , 2012, 25, 1740-1751.	1.7	65
27	Glutathione S-transferase pi trapping method for generation and characterization of drug-protein adducts in human liver microsomes using liquid chromatography-tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 67-68, 186-192.	1.4	14
28	Targeted Covalent Enzyme Inhibitors. <i>Annual Reports in Medicinal Chemistry</i> , 2012, , 413-439.	0.5	28
29	The determination and interpretation of the therapeutic index in drug development. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 751-761.	21.5	418
30	Preclinical Strategy to Reduce Clinical Hepatotoxicity Using in Vitro Bioactivation Data for >200 Compounds. <i>Chemical Research in Toxicology</i> , 2012, 25, 2067-2082.	1.7	105
31	The early estimation of circulating drug metabolites in humans. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 985-997.	1.5	10
32	Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles. <i>Nature Chemical Biology</i> , 2012, 8, 471-476.	3.9	408
33	On-chip electromembrane extraction for monitoring drug metabolism in real time by electrospray ionization mass spectrometry. <i>Analyst</i> , The, 2012, 137, 3321.	1.7	72
36	Haloarene Derivatives of Carbamazepine with Reduced Bioactivation Liabilities: 2-Monohalo and 2,8-Dihalo Derivatives. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 9773-9784.	2.9	18
37	Detection of nanolevel drug metabolites in an organotypic culture of primary human hepatocytes and porcine hepatocytes with special reference to a two-compartment model. <i>International Journal of Nanomedicine</i> , 2012, 7, 5859.	3.3	4
38	The Expanding Role of Electrospray Ionization Mass Spectrometry for Probing Reactive Intermediates in Solution. <i>Molecules</i> , 2012, 17, 11507-11537.	1.7	29
40	Radiolabeled Absorption, Distribution, Metabolism, and Excretion Studies in Drug Development: Why, When, and How?. <i>Chemical Research in Toxicology</i> , 2012, 25, 513-531.	1.7	138
41	The HepaRG cell line: a unique <i>in vitro</i> tool for understanding drug metabolism and toxicology in human. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 909-920.	1.5	187
42	Tritium: a coming of age for drug discovery and development ADME studies. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2012, 55, 235-257.	0.5	103
43	In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs. <i>Chemical Research in Toxicology</i> , 2012, 25, 1616-1632.	1.7	197

#	ARTICLE	IF	CITATIONS
45	Reversible Covalent Inhibition of a Protein Target. <i>Angewandte Chemie - International Edition</i> , 2012, 51, 8699-8700.	7.2	65
46	Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 6243-6262.	2.9	277
47	Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure-Activity Relationships and Discovery Strategies To Mitigate Drug-Drug Interaction Risks. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 4896-4933.	2.9	176
48	Identification and Characterization of Reactive Metabolites in Natural Products-Driven Drug Discovery. <i>Journal of Natural Products</i> , 2012, 75, 507-513.	1.5	29
49	Strategies to Mitigate the Bioactivation of 2-Anilino-7-Aryl-Pyrrolo[2,1- <i>f</i> ][1,2,4]triazines: Identification of Orally Bioavailable, Efficacious ALK Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 115-125.	2.9	28
50	Drug-Drug Interaction Potential of Marketed Oncology Drugs: In Vitro Assessment of Time-Dependent Cytochrome P450 Inhibition, Reactive Metabolite Formation and Drug-Drug Interaction Prediction. <i>Pharmaceutical Research</i> , 2012, 29, 1960-1976.	1.7	84
51	Established and Emerging Trends in Computational Drug Discovery in the Structural Genomics Era. <i>Chemistry and Biology</i> , 2012, 19, 29-41.	6.2	57
52	Primary hepatocyte cultures for pharmaco-toxicological studies: at the busy crossroad of various anti-dedifferentiation strategies. <i>Archives of Toxicology</i> , 2013, 87, 577-610.	1.9	105
53	Complementation of Biotransformations with Chemical C-H Oxidation: Copper-Catalyzed Oxidation of Tertiary Amines in Complex Pharmaceuticals. <i>Journal of the American Chemical Society</i> , 2013, 135, 12346-12352.	6.6	60
54	Glutathione metabolism modeling: A mechanism for liver drug-robustness and a new biomarker strategy. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2013, 1830, 4943-4959.	1.1	28
55	Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. <i>Archives of Toxicology</i> , 2013, 87, 1315-1530.	1.9	1,089
56	Cis-Amide isosteric replacement in thienobenzoxepin inhibitors of PI3-kinase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 897-901.	1.0	14
57	2-Amino-[1,2,4]triazolo[1,5- <i>a</i> ]pyridines as JAK2 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 5014-5021.	1.0	35
58	Questions regarding the predictive value of one evolved complex adaptive system for a second: Exemplified by the SOD1 mouse. <i>Progress in Biophysics and Molecular Biology</i> , 2013, 113, 231-253.	1.4	33
59	Pharmacogenetic Biomarkers as Tools for Pharmacoepidemiology of Severe Adverse Drug Reactions. <i>Drug Development Research</i> , 2013, 74, 1-14.	1.4	6
60	Preservation, induction or incorporation of metabolism into the in vitro cellular system - Views to current opportunities and limitations. <i>Toxicology in Vitro</i> , 2013, 27, 1578-1583.	1.1	10
61	High-throughput metabolic genotoxicity screening with a fluidic microwell chip and electrochemiluminescence. <i>Lab on A Chip</i> , 2013, 13, 4554.	3.1	29
62	Preparation of labeled human drug metabolites and drug-drug interaction-probes with fungal peroxygenases. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 513-519.	0.5	14

#	ARTICLE	IF	CITATIONS
63	Reversible inhibitors of regulators of G-protein signaling identified in a high-throughput cell-based calcium signaling assay. <i>Cellular Signalling</i> , 2013, 25, 2848-2855.	1.7	21
64	Multiscale modelling approach combining a kinetic model of glutathione metabolism with PBPK models of paracetamol and the potential glutathione-depletion biomarkers ophthalmic acid and 5-oxoproline in humans and rats. <i>Integrative Biology (United Kingdom)</i> , 2013, 5, 877-888.	0.6	34
65	Screening reactive metabolites bioactivated by multiple enzyme pathways using a multiplexed microfluidic system. <i>Analyst, The</i> , 2013, 138, 171-178.	1.7	16
66	Metabolism-guided drug design. <i>MedChemComm</i> , 2013, 4, 631.	3.5	84
67	The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. <i>Biochemical Pharmacology</i> , 2013, 85, 705-717.	2.0	855
68	A new twist to an old tale: novel insights into the differential toxicities of acetaminophen and its regioisomer N-acetyl-meta-aminophenol (AMAP). <i>Archives of Toxicology</i> , 2013, 87, 15-18.	1.9	7
69	Software aided approaches to structure-based metabolite identification in drug discovery and development. <i>Drug Discovery Today: Technologies</i> , 2013, 10, e207-e217.	4.0	30
71	N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11 $\beta$ -hydroxysteroid dehydrogenase type 1: Strategies to eliminate reactive metabolites. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 2344-2348.	1.0	11
72	Glucuronides from metabolites to medicines: a survey of the in vivo generation, chemical synthesis and properties of glucuronides. <i>Natural Product Reports</i> , 2013, 30, 806.	5.2	76
73	The Generation, Detection, and Effects of Reactive Drug Metabolites. <i>Medicinal Research Reviews</i> , 2013, 33, 985-1080.	5.0	73
74	Drug-Induced Liver Injury. , 2013, , 3-14.		36
75	Cytochrome P450 Activation of Toxins and Hepatotoxicity. , 2013, , 15-33.		4
76	Coexpression of CPR from Various Origins Enhances Biotransformation Activity of Human CYPs in <i>S. pombe</i> . <i>Applied Biochemistry and Biotechnology</i> , 2013, 170, 1751-1766.	1.4	23
77	Reactive Metabolite Trapping Studies on Imidazo- and 2-Methylimidazo[2,1- <i>b</i> ]thiazole-Based Inverse Agonists of the Ghrelin Receptor. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1375-1388.	1.7	7
78	Bioactivation of the Cannabinoid Receptor Antagonist Rimonabant to a Cytotoxic Iminium Ion Metabolite. <i>Chemical Research in Toxicology</i> , 2013, 26, 124-135.	1.7	18
79	Systematic Reviews of Animal Models: Methodology versus Epistemology. <i>International Journal of Medical Sciences</i> , 2013, 10, 206-221.	1.1	175
80	Idiosyncratic Adverse Drug Reactions: Current Concepts. <i>Pharmacological Reviews</i> , 2013, 65, 779-808.	7.1	253
82	Reactive Intermediates. <i>Toxicologic Pathology</i> , 2013, 41, 315-321.	0.9	6

#	ARTICLE	IF	CITATIONS
83	Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. <i>Hepatology</i> , 2013, 57, 727-739.	3.6	212
84	Gatekeepers and Enablers: How Drug Regulators Respond to a Challenging and Changing Environment by Moving Toward a Proactive Attitude. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 93, 425-432.	2.3	33
85	Avoiding idiosyncratic DILI: Two is better than one. <i>Hepatology</i> , 2013, 58, 15-17.	3.6	44
86	Animal Models in Drug Development. , 2013, , .		11
87	Current Concepts in Drug-Induced Bile Salt Export Pump (BSEP) Interference. <i>Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al ]</i> , 2014, 61, 23.7.1-15.	1.1	18
88	MicroRNAs as potential circulating biomarkers of drug-induced liver injury: key current and future issues for translation to humans. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 349-362.	1.3	44
89	Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2014, 24, 417-442.	2.4	27
90	A reflection on fit-for-purpose metabolite investigation at different stages of drug development. <i>Bioanalysis</i> , 2014, 6, 591-594.	0.6	0
91	Electrophilicity of Pyridazine-3-carbonitrile, Pyrimidine-2-carbonitrile, and Pyridine-carbonitrile Derivatives: A Chemical Model To Describe the Formation of Thiazoline Derivatives in Human Liver Microsomes. <i>Chemical Research in Toxicology</i> , 2014, 27, 2052-2061.	1.7	16
92	Cytochrome P450-Mediated Bioactivation of Mefenamic Acid to Quinoneimine Intermediates and Inactivation by Human Glutathione S-Transferases. <i>Chemical Research in Toxicology</i> , 2014, 27, 2071-2081.	1.7	29
93	Bilinear Model for the Size-Dependency of the CYP3A4 Inhibitory Activity of Structurally Diverse Compounds. <i>Molecular Informatics</i> , 2014, 33, 8-14.	1.4	2
94	Chemical Tuning Enhances Both Potency Toward Nrf2 and In Vitro Therapeutic Index of Triterpenoids. <i>Toxicological Sciences</i> , 2014, 140, 462-469.	1.4	21
95	A Correlation Between the In Vitro Drug Toxicity of Drugs to Cell Lines That Express Human P450s and Their Propensity to Cause Liver Injury in Humans. <i>Toxicological Sciences</i> , 2014, 137, 189-211.	1.4	64
96	Predicted multiple selected reaction monitoring to screen activated drug-mediated modifications on human serum albumin. <i>Analytical Biochemistry</i> , 2014, 449, 59-67.	1.1	14
97	Dapsone in dermatology and beyond. <i>Archives of Dermatological Research</i> , 2014, 306, 103-124.	1.1	261
98	High-throughput and combinatorial gene expression on a chip for metabolism-induced toxicology screening. <i>Nature Communications</i> , 2014, 5, 3739.	5.8	75
101	Liver X receptor 1 (LXR1/NR1H3) regulates differentiation of hepatocyte-like cells via reciprocal regulation of HNF4 $\alpha$ . <i>Journal of Hepatology</i> , 2014, 61, 1276-1286.	1.8	18
102	Post-acquisition analysis of untargeted accurate mass quadrupole time-of-flight MS data for multiple collision-induced neutral losses and fragment ions of glutathione conjugates. <i>Rapid Communications in Mass Spectrometry</i> , 2014, 28, 2695-2703.	0.7	30

#	ARTICLE	IF	CITATIONS
103	Demethylation of neferine in human liver microsomes and formation of quinone methide metabolites mediated by CYP3A4 accentuates its cytotoxicity. <i>Chemico-Biological Interactions</i> , 2014, 224, 89-99.	1.7	15
104	Emamectin benzoate treatment alters the expression and activity of CYP1A, FMO and GST in different tissues of rainbow trout ( <i>Oncorhynchus mykiss</i> ). <i>Aquaculture</i> , 2014, 434, 188-200.	1.7	6
105	Efficient synthesis of mibefradil analogues: an insight into in vitro stability. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 5669.	1.5	5
106	Development of a screening assay to evaluate the potential of drugs to cause immune-mediated hypersensitivity reactions. <i>Journal of Immunotoxicology</i> , 2014, 11, 110-115.	0.9	3
107	For a series of methylindole analogs, reactive metabolite formation is a poor predictor of intrinsic cytotoxicity in human hepatocytes. <i>Toxicology Research</i> , 2014, 3, 184.	0.9	5
108	Skin Sensitization Prediction Using Quantum Chemical Calculations: A Theoretical Model for the $S_{\text{Ar}}$ Domain. <i>Chemical Research in Toxicology</i> , 2014, 27, 51-60.	1.7	15
109	Design of Reversible, Cysteine-Targeted Michael Acceptors Guided by Kinetic and Computational Analysis. <i>Journal of the American Chemical Society</i> , 2014, 136, 12624-12630.	6.6	204
110	Facile and Efficient Oxidation of Quinazolines into Quinazolin-4(3 <i>H</i> )-ones by Peracetic Acid. <i>Synthetic Communications</i> , 2014, 44, 346-351.	1.1	6
112	Identification and Mitigation of a Reactive Metabolite Liability Associated with Aminoimidazoles. <i>Chemical Research in Toxicology</i> , 2014, 27, 1586-1597.	1.7	13
113	Elucidating the Origin of the Esterase Activity of Human Serum Albumin Using QM/MM Calculations. <i>Journal of Physical Chemistry B</i> , 2014, 118, 11886-11894.	1.2	29
114	<i>N</i> -Aryl-2-aminobenzimidazoles: Novel, Efficacious, Antimalarial Lead Compounds. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6642-6652.	2.9	37
115	Human NAD(P)H:quinone Oxidoreductase 1 (NQO1)-Mediated Inactivation of Reactive Quinoneimine Metabolites of Diclofenac and Mefenamic Acid. <i>Chemical Research in Toxicology</i> , 2014, 27, 576-586.	1.7	30
116	Zebrafish as model organisms for studying drug-induced liver injury. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 1217-1227.	1.1	150
117	Drug metabolism. <i>Resonance</i> , 2014, 19, 259-282.	0.2	24
118	Identification of Human Liver Microsomal Proteins Adducted by a Reactive Metabolite Using Shotgun Proteomics. <i>Chemical Research in Toxicology</i> , 2014, 27, 1537-1546.	1.7	9
119	Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. <i>Hepatology</i> , 2014, 60, 1015-1022.	3.6	188
120	The chemical, genetic and immunological basis of idiosyncratic drug-induced liver injury. <i>Human and Experimental Toxicology</i> , 2015, 34, 1310-1317.	1.1	28
123	Mechanism of quinine-dependent monoclonal antibody binding to platelet glycoprotein IIb/IIIa. <i>Blood</i> , 2015, 126, 2146-2152.	0.6	24

#	ARTICLE	IF	CITATIONS
124	Acetaminophen cytotoxicity is ameliorated in a human liver organotypic co-culture model. <i>Scientific Reports</i> , 2015, 5, 17455.	1.6	41
125	Glutathione trapping of reactive drug metabolites produced by biomimetic metalloporphyrin catalysts. <i>Rapid Communications in Mass Spectrometry</i> , 2015, 29, 521-532.	0.7	6
126	Structure-Activity Relationships of the Antitumor C5-Curcuminoid GO-Y030. <i>Molecules</i> , 2015, 20, 15374-15391.	1.7	22
127	Modeling of interactions between xenobiotics and cytochrome P450 (CYP) enzymes. <i>Frontiers in Pharmacology</i> , 2015, 6, 123.	1.6	65
128	Subtoxic Concentrations of Hepatotoxic Drugs Lead to Kupffer Cell Activation in a Human <i>In Vitro</i> Liver Model: An Approach to Study DILI. <i>Mediators of Inflammation</i> , 2015, 2015, 1-14.	1.4	29
130	Detecting reactive drug metabolites for reducing the potential for drug toxicity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1281-1302.	1.5	36
131	Electrocatalysis by subcellular liver fractions bound to carbon nanostructures for stereoselective green drug metabolite synthesis. <i>Chemical Communications</i> , 2015, 51, 11681-11684.	2.2	21
132	Biokinetics in repeated-dosing in vitro drug toxicity studies. <i>Toxicology in Vitro</i> , 2015, 30, 217-224.	1.1	80
133	Multiple Compound-Related Adverse Properties Contribute to Liver Injury Caused by Endothelin Receptor Antagonists. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 352, 281-290.	1.3	41
134	Discovery of Small Molecule CD40 TRAF6 Inhibitors. <i>Journal of Chemical Information and Modeling</i> , 2015, 55, 294-307.	2.5	58
135	Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: An in vitro study. <i>Epilepsia</i> , 2015, 56, 439-449.	2.6	23
136	Biotransformation in vitro: An essential consideration in the quantitative in vitro-to-in vivo extrapolation (QIVIVE) of toxicity data. <i>Toxicology</i> , 2015, 332, 8-19.	2.0	71
137	An in vitro liver model on microfluidic device for analysis of capecitabine metabolite using mass spectrometer as detector. <i>Biosensors and Bioelectronics</i> , 2015, 68, 322-328.	5.3	58
138	The Design of Covalent Allosteric Drugs. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 249-267.	4.2	96
139	Electrochemistry-mass spectrometry to study reactive drug metabolites and CYP450 simulations. <i>TrAC - Trends in Analytical Chemistry</i> , 2015, 70, 67-73.	5.8	33
140	Formation of GSH-trapped reactive metabolites in human liver microsomes, S9 fraction, HepaRG-cells, and human hepatocytes. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 115, 345-351.	1.4	16
141	Modeling Epoxidation of Drug-like Molecules with a Deep Machine Learning Network. <i>ACS Central Science</i> , 2015, 1, 168-180.	5.3	130
142	Tracking Where the TM's Go. <i>ACS Central Science</i> , 2015, 1, 163-165.	5.3	1



#	ARTICLE	IF	CITATIONS
143	Targeted Data-Independent Acquisition and Mining Strategy for Trace Drug Metabolite Identification Using Liquid Chromatography Coupled with Tandem Mass Spectrometry. <i>Analytical Chemistry</i> , 2015, 87, 7535-7539.	3.2	23
144	One-pot synthesis of human metabolites of SAR548304 by fungal peroxxygenases. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 4324-4332.	1.4	22
145	Drug-induced liver injury: Interactions between drug properties and host factors. <i>Journal of Hepatology</i> , 2015, 63, 503-514.	1.8	319
146	Characterization of RA839, a Noncovalent Small Molecule Binder to Keap1 and Selective Activator of Nrf2 Signaling. <i>Journal of Biological Chemistry</i> , 2015, 290, 28446-28455.	1.6	78
147	New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 236-244.	1.5	80
148	Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6844-6863.	2.9	92
149	Non-target UHPLC/MS Analysis of Emerging Contaminants in Water. <i>Environmental Chemistry for A Sustainable World</i> , 2015, , 123-167.	0.3	2
150	Evidence for the <i>in Vitro</i> Bioactivation of Aminopyrazole Derivatives: Trapping Reactive Aminopyrazole Intermediates Using Glutathione Ethyl Ester in Human Liver Microsomes. <i>Chemical Research in Toxicology</i> , 2015, 28, 1747-1752.	1.7	7
151	Toxicity Originating from Thiophene Containing Drugs: Exploring the Mechanism using Quantum Chemical Methods. <i>Chemical Research in Toxicology</i> , 2015, 28, 2364-2376.	1.7	35
152	Practical approaches to resolving reactive metabolite liabilities in early discovery. <i>Drug Metabolism Reviews</i> , 2015, 47, 56-70.	1.5	32
153	Predicting Toxicities of Reactive Metabolite-Positive Drug Candidates. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 35-54.	4.2	91
154	Transcriptional profiling of reactive metabolites for elucidating toxicological mechanisms: a case study of quinoneimine-forming agents. <i>Drug Metabolism Reviews</i> , 2015, 47, 45-55.	1.5	4
155	Access to drug metabolites via C-H functionalization: copper-catalyzed aerobic oxidation of N,N-dimethylalkylamines in complex pharmaceuticals. <i>Tetrahedron Letters</i> , 2015, 56, 3066-3069.	0.7	14
156	Analytical challenges for conducting rapid metabolism characterization for QIVIVE. <i>Toxicology</i> , 2015, 332, 20-29.	2.0	22
157	Key Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation Plans. <i>BioMed Research International</i> , 2016, 2016, 1-20.	0.9	44
158	The Significance of Discovery Screening and Structure Optimization Studies. , 2016, , 109-128.		9
159	Integrated Computational Approach for Virtual Hit Identification against Ebola Viral Proteins VP35 and VP40. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1748.	1.8	37
160	Covalent Inhibition of HIV-1 Integrase by N-Succinimidyl Peptides. <i>ChemMedChem</i> , 2016, 11, 1987-1994.	1.6	5

#	ARTICLE	IF	CITATIONS
161	The Keap1â€Nrf2â€ARE Pathway As a Potential Preventive and Therapeutic Target: An Update. Medicinal Research Reviews, 2016, 36, 924-963.	5.0	562
162	A Model to predict severity of drugâ€induced liver injury in humans. Hepatology, 2016, 64, 931-940.	3.6	74
163	Roles of Nrf2 in drug and chemical toxicity. Current Opinion in Toxicology, 2016, 1, 104-110.	2.6	20
164	Prototype Systems Containing Human Cytochrome P450 for High-Throughput Real-Time Detection of DNA Damage by Compounds That Form DNA-Reactive Metabolites. Chemical Research in Toxicology, 2016, 29, 747-756.	1.7	2
165	Characterizing novel metabolic pathways of melatonin receptor agonist agomelatine using metabolomic approaches. Biochemical Pharmacology, 2016, 109, 70-82.	2.0	32
166	Inhibition of Zinc-Dependent Histone Deacetylases with a Chemically Triggered Electrophile. ACS Chemical Biology, 2016, 11, 1844-1851.	1.6	21
167	Protein Targets of Isoniazid-Reactive Metabolites in Mouse Liver <i>in Vivo</i>. Chemical Research in Toxicology, 2016, 29, 1064-1072.	1.7	11
168	Mass Spectrometric and Functional Aspects of Drugâ€Protein Conjugation. Chemical Research in Toxicology, 2016, 29, 1912-1935.	1.7	48
169	Development of a Terpenoid Alkaloidâ€Like Compound Library Based on the Humulene Skeleton. Chemistry - A European Journal, 2016, 22, 15819-15825.	1.7	21
170	Microfluidic array for simultaneous detection of DNA oxidation and DNA-adduct damage. Analyst, The, 2016, 141, 5722-5729.	1.7	9
174	Reversibility of the thia-Michael reaction of cytotoxic C<sub>5</sub>-curcuminoid and structureâ€activity relationship of bis-thiol-adducts thereof. Organic and Biomolecular Chemistry, 2016, 14, 10683-10687.	1.5	17
175	Phase I Metabolic Stability and Electrophilic Reactivity of 2-Phenylaminophenylacetic Acid Derived Compounds. Chemical Research in Toxicology, 2016, 29, 1118-1131.	1.7	3
176	Identification of N-Oxide and Sulfoxide Functionalities in Protonated Drug Metabolites by Using Ionâ€Molecule Reactions Followed by Collisionally Activated Dissociation in a Linear Quadrupole Ion Trap Mass Spectrometer. Journal of Organic Chemistry, 2016, 81, 575-586.	1.7	22
177	Reactive Metabolites: Current and Emerging Risk and Hazard Assessments. Chemical Research in Toxicology, 2016, 29, 505-533.	1.7	114
178	Safety Lead Optimization and Candidate Identification: Integrating New Technologies into Decision-Making. Chemical Research in Toxicology, 2016, 29, 452-472.	1.7	24
179	Toxicology Strategies for Drug Discovery: Present and Future. Chemical Research in Toxicology, 2016, 29, 473-504.	1.7	157
180	Phase II metabolic pathways of spectinamide antitubercular agents: a comparative study of the reactivity of 4-substituted pyridines to glutathione conjugation. MedChemComm, 2016, 7, 114-117.	3.5	11
181	Role of miRNA and its potential as a novel diagnostic biomarker in drug-induced liver injury. European Journal of Clinical Pharmacology, 2017, 73, 399-407.	0.8	20

#	ARTICLE	IF	CITATIONS
182	The Opportunities of Metabolomics in Drug Safety Evaluation. <i>Current Pharmacology Reports</i> , 2017, 3, 10-15.	1.5	16
183	Transcriptional, Functional, and Mechanistic Comparisons of Stem Cell-Derived Hepatocytes, HepaRG Cells, and Three-Dimensional Human Hepatocyte Spheroids as Predictive In Vitro Systems for Drug-Induced Liver Injury. <i>Drug Metabolism and Disposition</i> , 2017, 45, 419-429.	1.7	141
184	Generic method for the absolute quantification of glutathione S-conjugates: Application to the conjugates of acetaminophen, clozapine and diclofenac. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1046, 185-194.	1.2	4
185	Potent covalent inhibitors of bacterial urease identified by activity-reactivity profiling. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1346-1350.	1.0	17
186	Human biology-based drug safety evaluation: scientific rationale, current status and future challenges. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 567-574.	1.5	4
187	Definition of the Nature and Hapten Threshold of the $\beta$ -Lactam Antigen Required for T Cell Activation In Vitro and in Patients. <i>Journal of Immunology</i> , 2017, 198, 4217-4227.	0.4	54
188	Computational analysis of calculated physicochemical and ADMET properties of protein-protein interaction inhibitors. <i>Scientific Reports</i> , 2017, 7, 46277.	1.6	128
189	Quantitative Chemical Proteomic Profiling of the <i>in Vivo</i> Targets of Reactive Drug Metabolites. <i>ACS Chemical Biology</i> , 2017, 12, 2040-2050.	1.6	34
190	The Role of Drug Metabolites in the Inhibition of Cytochrome P450 Enzymes. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 881-890.	0.6	9
191	Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 767-782.	1.5	30
192	Why Prodrugs and Propesticides Succeed. <i>Chemical Research in Toxicology</i> , 2017, 30, 1117-1126.	1.7	30
193	Sulfonamides as Selective Na <sup>V</sup> 1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5969-5989.	2.9	42
194	Sulfonamides as Selective Na <sup>V</sup> 1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust <i>In Vivo</i> Activity. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5990-6017.	2.9	56
195	Mitigation of reactive metabolite formation for a series of 3-amino-2-pyridone inhibitors of Bruton's tyrosine kinase (BTK). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 632-635.	1.0	8
196	Biomonitoring Human Albumin Adducts: The Past, the Present, and the Future. <i>Chemical Research in Toxicology</i> , 2017, 30, 332-366.	1.7	89
197	Methanol adducts leading to the identification of a reactive aldehyde metabolite of CPAQOP in human liver microsomes by ultra-high-performance liquid chromatography/mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2017, 31, 145-151.	0.7	1
198	Evaluating Metabolite-Related DNA Oxidation and Adduct Damage from Aryl Amines Using a Microfluidic ECL Array. <i>Analytical Chemistry</i> , 2017, 89, 12441-12449.	3.2	21
199	Ketone Body Acetoacetate Buffers Methylglyoxal via a Non-enzymatic Conversion during Diabetic and Dietary Ketosis. <i>Cell Chemical Biology</i> , 2017, 24, 935-943.e7.	2.5	32

#	ARTICLE	IF	CITATIONS
200	Enhanced Hepatic Functions of Genetically Modified Mouse Hepatoma Cells by Spheroid Culture for Drug Toxicity Screening. <i>Biotechnology Journal</i> , 2017, 12, 1700274.	1.8	17
201	Development of (4-Cyanophenyl)glycine Derivatives as Reversible Inhibitors of Lysine Specific Demethylase 1. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7984-7999.	2.9	38
202	LC-MS/MS reveals the formation of aldehydes and iminium reactive intermediates in foretinib metabolism: phase I metabolic profiling. <i>RSC Advances</i> , 2017, 7, 36279-36287.	1.7	31
203	Anticancer potency of nitric oxide-releasing liposomes. <i>RSC Advances</i> , 2017, 7, 53236-53246.	1.7	14
204	Strategy for Hepatotoxicity Prediction Induced by Drug Reactive Metabolites Using Human Liver Microsome and Online 2D-Nano-LC-MS Analysis. <i>Analytical Chemistry</i> , 2017, 89, 13167-13175.	3.2	20
205	The Keap1-Nrf2 protein-protein interaction: A suitable target for small molecules. <i>Drug Discovery Today: Technologies</i> , 2017, 24, 11-17.	4.0	40
206	Evaluation of the metabolism, bioactivation and pharmacokinetics of triaminopyrimidine analogs toward selection of a potential candidate for antimalarial therapy. <i>Xenobiotica</i> , 2017, 47, 962-972.	0.5	0
207	Stem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injury. <i>Hepatology</i> , 2017, 65, 710-721.	3.6	54
208	Minimizing the risk of chemically reactive metabolite formation of new drug candidates: implications for preclinical drug design. <i>Drug Discovery Today</i> , 2017, 22, 751-756.	3.2	29
209	Concise Review: Organ Engineering: Design, Technology, and Integration. <i>Stem Cells</i> , 2017, 35, 51-60.	1.4	48
210	Revisiting the Metabolism and Bioactivation of Ketoconazole in Human and Mouse Using Liquid Chromatography-Mass Spectrometry-Based Metabolomics. <i>International Journal of Molecular Sciences</i> , 2017, 18, 621.	1.8	36
211	Inhibitory Effects of Trapping Agents of Sulfur Drug Reactive Intermediates against Major Human Cytochrome P450 Isoforms. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1553.	1.8	6
212	Drug-Induced Liver Injury: Mechanism-Informed Prediction in Drug Development. , 2017, , 217-238.		3
213	A new approach for the assessment of the toxicity of polyphenol-rich compounds with the use of high content screening analysis. <i>PLoS ONE</i> , 2017, 12, e0180022.	1.1	35
214	Drug Metabolism in Preclinical Drug Development: A Survey of the Discovery Process, Toxicology, and Computational Tools. <i>Current Drug Metabolism</i> , 2017, 18, 556-565.	0.7	81
216	Multiobjective Optimization of Biological and Physical Properties in Drug Discovery. , 2017, , 64-93.		0
218	Biomimetic trapping cocktail to screen reactive metabolites: use of an amino acid and DNA motif mixture as light/heavy isotope pairs differing in mass shift. <i>Analytical and Bioanalytical Chemistry</i> , 2018, 410, 3847-3857.	1.9	2
219	Identification and Mitigation of Reactive Metabolites of 2-Aminoimidazole-Containing Microsomal Prostaglandin E Synthase-1 Inhibitors Terminated Due to Clinical Drug-Induced Liver Injury. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2041-2051.	2.9	24

#	ARTICLE	IF	CITATIONS
220	Reduction and Scavenging of Chemically Reactive Drug Metabolites by NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 and Variability in Hepatic Concentrations. <i>Chemical Research in Toxicology</i> , 2018, 31, 116-126.	1.7	14
221	Rapid screening and characterization of glutathione-trapped reactive metabolites using a polarity switch-based approach on a high-resolution quadrupole orbitrap mass spectrometer. <i>Analytical and Bioanalytical Chemistry</i> , 2018, 410, 1595-1606.	1.9	7
222	Comparison of Hepatic 2D Sandwich Cultures and 3D Spheroids for Long-term Toxicity Applications: A Multicenter Study. <i>Toxicological Sciences</i> , 2018, 162, 655-666.	1.4	219
223	LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways. <i>RSC Advances</i> , 2018, 8, 1182-1190.	1.7	28
224	Role of Glucuronidation and P450 Oxidation in the Bioactivation of Bromfenac. <i>Chemical Research in Toxicology</i> , 2018, 31, 223-230.	1.7	8
226	Reactive Metabolite Assessment in Drug Discovery and Development in Support of Safe Drug Design. <i>Methods in Pharmacology and Toxicology</i> , 2018, , 263-281.	0.1	2
227	Interpretation, Integration, and Implementation of In Vitro Assay Data: The Predictive Toxicity Challenge. <i>Methods in Pharmacology and Toxicology</i> , 2018, , 345-364.	0.1	2
228	Detection, Elimination, Mitigation, and Prediction of Drug-Induced Liver Injury in Drug Discovery. <i>Methods in Pharmacology and Toxicology</i> , 2018, , 21-43.	0.1	1
229	Immune Mechanisms in Drug-Induced Liver Injury. <i>Methods in Pharmacology and Toxicology</i> , 2018, , 511-531.	0.1	2
230	Physicochemical Properties and Structural Alerts. <i>Methods in Pharmacology and Toxicology</i> , 2018, , 61-76.	0.1	4
231	<i>In silico</i> Predicted Glucose-6-phosphate Uridyltransferase (GalU) Inhibitors Block a Key Pathway Required for <i>Listeria</i> Virulence. <i>Molecular Informatics</i> , 2018, 37, e1800004.	1.4	15
232	CONET: a virtual human system-centered platform for drug discovery. <i>Frontiers of Computer Science</i> , 2018, 12, 1-3.	1.6	15
233	Deuterium- and tritiummarkierte Verbindungen: Anwendungen in den modernen Biowissenschaften. <i>Angewandte Chemie</i> , 2018, 130, 1774-1802.	1.6	104
234	Modulations of Keap1-Nrf2 signaling axis by TIIA ameliorated the oxidative stress-induced myocardial apoptosis. <i>Free Radical Biology and Medicine</i> , 2018, 115, 191-201.	1.3	44
235	Deuterium- and Tritium-Labelled Compounds: Applications in the Life Sciences. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 1758-1784.	7.2	488
236	Characterization of reactive intermediates formation in dacomitinib metabolism and bioactivation pathways elucidation by LC-MS/MS: <i>in vitro</i> phase I metabolic investigation. <i>RSC Advances</i> , 2018, 8, 38733-38744.	1.7	14
237	Profiling of Methylglyoxal Blood Metabolism and Advanced Glycation End-Product Proteome Using a Chemical Probe. <i>ACS Chemical Biology</i> , 2018, 13, 3294-3305.	1.6	26
238	Identification and characterization of <i>in vivo</i> , <i>in vitro</i> and reactive metabolites of vandetanib using LC-ESI-MS/MS. <i>Chemistry Central Journal</i> , 2018, 12, 99.	2.6	33

#	ARTICLE	IF	CITATIONS
239	Investigation of the Nrf2 Stress Response at Cellular Level to Detect Compounds Inducing Oxidative and Electrophilic Stress. <i>Applied in Vitro Toxicology</i> , 2018, 4, 248-264.	0.6	0
240	Drug metabolism and metabolite safety assessment in drug discovery and development. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 1071-1085.	1.5	57
241	Development of simultaneous targeted metabolite quantification and untargeted metabolomics strategy using dual-column liquid chromatography coupled with tandem mass spectrometry. <i>Analytica Chimica Acta</i> , 2018, 1037, 369-379.	2.6	24
242	Application of hepatocyte-like cells to enhance hepatic safety risk assessment in drug discovery. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2018, 373, 20170228.	1.8	21
243	A systematic approach to identify therapeutic effects of natural products based on human metabolite information. <i>BMC Bioinformatics</i> , 2018, 19, 205.	1.2	7
245	The Metabolism of Separase Inhibitor Sepin-1 in Human, Mouse, and Rat Liver Microsomes. <i>Frontiers in Pharmacology</i> , 2018, 9, 313.	1.6	7
246	LC-MS/MS reveals the formation of iminium and quinone methide reactive intermediates in entrectinib metabolism: In vivo and in vitro metabolic investigation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 160, 19-30.	1.4	37
247	Identification of Specific MicroRNA Biomarkers in Early Stages of Hepatocellular Injury, Cholestasis, and Steatosis in Rats. <i>Toxicological Sciences</i> , 2018, 166, 228-239.	1.4	32
248	Genetic polymorphism of glutathione S-transferases: Relevance to neurological disorders. <i>Pathophysiology</i> , 2018, 25, 285-292.	1.0	26
249	Identification and Pharmacological Profile of an Indane Based Series of Ghrelin Receptor Full Agonists. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5974-5987.	2.9	13
250	Endoplasmic reticulum stress signalling – from basic mechanisms to clinical applications. <i>FEBS Journal</i> , 2019, 286, 241-278.	2.2	568
251	Liquid chromatography-tandem mass spectrometry metabolic profiling of nazartinib reveals the formation of unexpected reactive metabolites. <i>Royal Society Open Science</i> , 2019, 6, 190852.	1.1	3
252	Risk factors associated with the incidence and time to onset of lapatinib-induced hepatotoxicity. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 239-244.	1.1	10
253	A Time-Embedding Network Models the Ontogeny of 23 Hepatic Drug Metabolizing Enzymes. <i>Chemical Research in Toxicology</i> , 2019, 32, 1707-1721.	1.7	6
254	Enzymes and Pathways of Kavain Bioactivation and Biotransformation. <i>Chemical Research in Toxicology</i> , 2019, 32, 1335-1342.	1.7	4
255	Encoding information in synthetic metabolomes. <i>PLoS ONE</i> , 2019, 14, e0217364.	1.1	18
256	Drug-induced liver injury. <i>Nature Reviews Disease Primers</i> , 2019, 5, 58.	18.1	409
257	Molecular docking, drug-likeness, and ADMET study of 1-benzyl-3-benzoylurea and its analogs against VEGFR-2. <i>IOP Conference Series: Earth and Environmental Science</i> , 2019, 293, 012018.	0.2	1

#	ARTICLE	IF	CITATIONS
258	Bioactivation of herbal constituents: mechanisms and toxicological relevance. <i>Drug Metabolism Reviews</i> , 2019, 51, 453-497.	1.5	11
259	Predicting the Risks of Drug-Induced Liver Injury in Humans Utilizing Computational Modeling. <i>Challenges and Advances in Computational Chemistry and Physics</i> , 2019, , 259-278.	0.6	0
260	Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug-drug interactions and hepatotoxicity. <i>Medicinal Research Reviews</i> , 2019, 39, 2105-2152.	5.0	25
261	Liver Microphysiological Systems for Predicting and Evaluating Drug Effects. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 139-147.	2.3	48
262	Novel risk assessment of reactive metabolites from discovery to clinical stage. <i>Journal of Toxicological Sciences</i> , 2019, 44, 201-211.	0.7	9
263	A potent seven-membered cyclic BTK (Bruton's tyrosine Kinase) chiral inhibitor conceived by structure-based drug design to lock its bioactive conformation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 1074-1078.	1.0	6
264	Integrated in vitro models for hepatic safety and metabolism: evaluation of a human Liver-Chip and liver spheroid. <i>Archives of Toxicology</i> , 2019, 93, 1021-1037.	1.9	77
265	EASL Clinical Practice Guidelines: Drug-induced liver injury. <i>Journal of Hepatology</i> , 2019, 70, 1222-1261.	1.8	629
266	Reactive intermediates in naquotinib metabolism identified by liquid chromatography-tandem mass spectrometry: phase I metabolic profiling. <i>RSC Advances</i> , 2019, 9, 10211-10225.	1.7	2
267	Reactive intermediates in copanlisib metabolism identified by LC-MS/MS: phase I metabolic profiling. <i>RSC Advances</i> , 2019, 9, 6409-6418.	1.7	6
268	Covalent Inhibition in Drug Discovery. <i>ChemMedChem</i> , 2019, 14, 889-906.	1.6	168
269	Reactive intermediates and bioactivation pathways characterization of avitinib by LC-MS/MS: In vitro metabolic investigation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 164, 659-667.	1.4	37
270	Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injury. <i>Archives of Toxicology</i> , 2019, 93, 385-399.	1.9	23
271	RA-839, a selective agonist of Nrf2/ARE pathway, exerts potent anti-rotaviral efficacy in vitro. <i>Antiviral Research</i> , 2019, 161, 53-62.	1.9	23
272	Phase I and phase II metabolism simulation of antitumor-active 2-hydroxyacridinone with electrochemistry coupled on-line with mass spectrometry. <i>Xenobiotica</i> , 2019, 49, 922-934.	0.5	9
273	A high-throughput glutathione trapping assay with combined high sensitivity and specificity in high-resolution mass spectrometry by applying product ion extraction and data-dependent neutral loss. <i>Journal of Mass Spectrometry</i> , 2019, 54, 158-166.	0.7	9
274	Three-Level Hepatotoxicity Prediction System Based on Adverse Hepatic Effects. <i>Molecular Pharmaceutics</i> , 2019, 16, 393-408.	2.3	19
275	Involvement of Pazopanib and Sunitinib Aldehyde Reactive Metabolites in Toxicity and Drug-Drug Interactions <i>in Vitro</i> and in Patient Samples. <i>Chemical Research in Toxicology</i> , 2020, 33, 181-190.	1.7	16

#	ARTICLE	IF	CITATIONS
276	Predicting Drug-Induced Liver Injury with Bayesian Machine Learning. <i>Chemical Research in Toxicology</i> , 2020, 33, 239-248.	1.7	69
277	Bioactivation of GPR40 Agonist MK-8666: Formation of Protein Adducts in Vitro from Reactive Acyl Glucuronide and Acyl CoA Thioester. <i>Chemical Research in Toxicology</i> , 2020, 33, 191-201.	1.7	16
278	Bioanalytical challenges and strategies for accurately measuring acyl glucuronide metabolites in biological fluids. <i>Biomedical Chromatography</i> , 2020, 34, e4640.	0.8	9
279	Definition of the Chemical and Immunological Signals Involved in Drug-Induced Liver Injury. <i>Chemical Research in Toxicology</i> , 2020, 33, 61-76.	1.7	17
280	Isoquinoline Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-like 2 (KEAP1-NRF2) Inhibitors with High Metabolic Stability. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 6547-6560.	2.9	36
281	Application of Negative Design To Design a More Desirable Virtual Screening Library. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4411-4429.	2.9	19
282	Detection and characterization of olmutinib reactive metabolites by LC-MS/MS: Elucidation of bioactivation pathways. <i>Journal of Separation Science</i> , 2020, 43, 708-718.	1.3	28
283	Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 131-148.	21.5	153
284	Covalent Small Molecules as Enabling Platforms for Drug Discovery. <i>ChemBioChem</i> , 2020, 21, 1080-1100.	1.3	64
285	Unveiling the molecular mechanism of SARS-CoV-2 main protease inhibition from 137 crystal structures using algebraic topology and deep learning. <i>Chemical Science</i> , 2020, 11, 12036-12046.	3.7	62
286	Mechanistic studies on the drug metabolism and toxicity originating from cytochromes P450. <i>Drug Metabolism Reviews</i> , 2020, 52, 366-394.	1.5	18
287	The Most Common Functional Groups in Bioactive Molecules and How Their Popularity Has Evolved over Time. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 8408-8418.	2.9	163
288	Nicotinamide N-Methyltransferase Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric Cancer. <i>Frontiers in Genetics</i> , 2020, 11, 580299.	1.1	11
289	Metabolic Forest: Predicting the Diverse Structures of Drug Metabolites. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 4702-4716.	2.5	11
290	&lt;p&gt;Characterization of Stable and Reactive Metabolites of the Anticancer Drug, Ensartinib, in Human Liver Microsomes Using LC-MS/MS: An in silico and Practical Bioactivation Approach&lt;p&gt;, <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 5259-5273.	2.0	3
291	Identification of Iminium Intermediates Generation in the Metabolism of Tepotinib Using LC-MS/MS: In Silico and Practical Approaches to Bioactivation Pathway Elucidation. <i>Molecules</i> , 2020, 25, 5004.	1.7	12
292	TiO <sub>2</sub> -modified MALDI target for in vitro modeling of the oxidative biotransformation of diclofenac. <i>Mendeleev Communications</i> , 2020, 30, 220-222.	0.6	4
293	Strategies to Mitigate the Bioactivation of Aryl Amines. <i>Chemical Research in Toxicology</i> , 2020, 33, 1950-1959.	1.7	10



#	ARTICLE	IF	CITATIONS
294	Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies. Journal of Medicinal Chemistry, 2020, 63, 11397-11419.	2.9	55
295	Application of a Rat Liver Drug Bioactivation Transcriptional Response Assay Early in Drug Development That Informs Chemically Reactive Metabolite Formation and Potential for Drug-induced Liver Injury. Toxicological Sciences, 2020, 177, 281-299.	1.4	27
296	Comprehensive <i>In Vitro</i> Metabolism Study of Bisphenol A Using Liquid Chromatography-High Resolution Tandem Mass Spectrometry. Chemical Research in Toxicology, 2020, 33, 1468-1477.	1.7	12
297	Effective Application of Metabolite Profiling in Drug Design and Discovery. Journal of Medicinal Chemistry, 2020, 63, 6387-6406.	2.9	25
299	Functionality of primary hepatic non-parenchymal cells in a 3D spheroid model and contribution to acetaminophen hepatotoxicity. Archives of Toxicology, 2020, 94, 1251-1263.	1.9	25
300	Chemical synthesis of 5 <sup>TM</sup> - $\beta$ -glycoconjugates of vitamin B6. Carbohydrate Research, 2020, 489, 107940.	1.1	1
301	Phase I metabolic profiling and unexpected reactive metabolites in human liver microsome incubations of X-376 using LC-MS/MS: bioactivation pathway elucidation and <i>in silico</i> toxicity studies of its metabolites. RSC Advances, 2020, 10, 5412-5427.	1.7	31
302	Tissue engineering: current status and future perspectives. , 2020, , 1-35.		22
303	MymA Bioactivated Thioalkylbenzoxazole Prodrug Family Active against <i>Mycobacterium tuberculosis</i> . Journal of Medicinal Chemistry, 2020, 63, 4732-4748.	2.9	12
304	Cyclovirobuxine D protects against diabetic cardiomyopathy by activating Nrf2-mediated antioxidant responses. Scientific Reports, 2020, 10, 6427.	1.6	21
305	Approaches to mitigate the risk of serious adverse reactions in covalent drug design. Expert Opinion on Drug Discovery, 2021, 16, 275-287.	2.5	17
306	Human superoxide dismutase 1 attenuates quinoneimine metabolite formation from mefenamic acid. Toxicology, 2021, 448, 152648.	2.0	1
307	Machine Learning in Predictive Toxicology: Recent Applications and Future Directions for Classification Models. Chemical Research in Toxicology, 2021, 34, 217-239.	1.7	51
308	Evaluation of covalent binding of flutamide and its risk assessment using <sup>19</sup> F-NMR. Xenobiotica, 2021, 51, 88-94.	0.5	4
309	Fragment-based covalent ligand discovery. RSC Chemical Biology, 2021, 2, 354-367.	2.0	65
310	The emergence of the C-H functionalization strategy in medicinal chemistry and drug discovery. Chemical Communications, 2021, 57, 10842-10866.	2.2	52
311	Characteristics of Major Drug Metabolizing Cytochrome P450 Enzymes. Methods in Pharmacology and Toxicology, 2021, , 27-54.	0.1	2
312	Engineering Selectivity for Reduced Toxicity of Bacterial Kinase Inhibitors Using Structure-Guided Medicinal Chemistry. ACS Medicinal Chemistry Letters, 2021, 12, 228-235.	1.3	3

#	ARTICLE	IF	CITATIONS
313	Antiparkinsonian activity of Cucurbita pepo seeds along with possible underlying mechanism. <i>Metabolic Brain Disease</i> , 2021, 36, 1231-1251.	1.4	15
315	In-Vitro Approaches to Predict and Study T-Cell Mediated Hypersensitivity to Drugs. <i>Frontiers in Immunology</i> , 2021, 12, 630530.	2.2	13
316	Recent advances in computational metabolite structure predictions and altered metabolic pathways assessment to inform drug development processes. <i>Drug Metabolism Reviews</i> , 2021, 53, 173-187.	1.5	2
317	Bio-activation of simeprevir in liver microsomes and characterization of its glutathione conjugates by liquid chromatography coupled to ultrahigh-resolution quadrupole time-of-flight mass spectrometry. <i>Journal of Chromatography A</i> , 2021, 1645, 462095.	1.8	4
318	Identification of average molecular weight (AMW) as a useful chemical descriptor to discriminate liver injury-inducing drugs. <i>PLoS ONE</i> , 2021, 16, e0253855.	1.1	2
319	The evolution of the concept of stress and the framework of the stress system. <i>Cell Stress</i> , 2021, 5, 76-85.	1.4	64
320	Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors. <i>Metabolites</i> , 2021, 11, 390.	1.3	3
323	Protein Targets of Acetaminophen Covalent Binding in Rat and Mouse Liver Studied by LC-MS/MS. <i>Frontiers in Chemistry</i> , 2021, 9, 736788.	1.8	5
324	Development of fluorescent-labeled trapping reagents based on cysteine to detect soft and hard electrophilic reactive metabolites. <i>Drug Metabolism and Pharmacokinetics</i> , 2021, 39, 100386.	1.1	4
325	Next-Generation Intestinal Toxicity Model of Human Embryonic Stem Cell-Derived Enterocyte-Like Cells. <i>Frontiers in Veterinary Science</i> , 2021, 8, 587659.	0.9	3
326	Efficacy and safety of levetiracetam versus (fos)phenytoin for second-line treatment of epilepticus: a meta-analysis of latest randomized controlled trials. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2021, 91, 339-345.	0.9	10
327	Identification and characterization of in vitro, in vivo, and reactive metabolites of tandutinib using liquid chromatography ion trap mass spectrometry. <i>Analytical Methods</i> , 2021, 13, 399-410.	1.3	6
330	Synthesis of cyclophosphamide metabolites by a peroxygenase from <i>Marasmius rotula</i> for toxicological studies on human cancer cells. <i>AMB Express</i> , 2020, 10, 128.	1.4	12
331	A Discussion of the Role of Complex Evolved Systems in the Development of Invasive Cardiovascular Interventions as Illustrated by the Blalock- Taussig Shunt and Intra-Arterial Stents. <i>Biological Systems</i> , Open Access, 2014, 03, .	0.1	3
332	New Insights into Toxicity and Drug Testing. , 2013, , .		6
333	Drug Induced Liver Injury. , 2022, , 411-442.		1
334	Reactive metabolites of the anticonvulsant drugs and approaches to minimize the adverse drug reaction. <i>European Journal of Medicinal Chemistry</i> , 2021, 226, 113890.	2.6	19
335	Psychopharmaka-Entwicklung: von der Entdeckung bis zur Zulassung. , 2012, , 87-104.		0

#	ARTICLE	IF	CITATIONS
336	Toxicodynamics: How Chemicals Harm Cells. , 2014, , 91-125.		0
337	Consideration of Metabolism in In Vitro Cellular Systems. Methods in Pharmacology and Toxicology, 2014, , 501-519.	0.1	0
341	CHEMOTERAPEUTIKUM DAPSON - ZÁKLADNĀ•CHARAKTERISTIKA A ZAJĀMAVĀ% VĀŠLEDKY KLINICKĀCH STUDIĀ• Military Medical Science Letters (Vojenske Zdravotnicke Listy), 2017, 86, 114-121.	0.2	0
343	ADME Principles in Small Molecule Drug Discovery and Development: An Industrial Perspective. , 2022, , 51-76.		2
344	Site-specific protein modification by 3-n-butylphthalide in primary hepatocytes: Covalent protein adducts diminished by glutathione and N-acetylcysteine. Life Sciences, 2021, 287, 120125.	2.0	1
345	A novel synthetic protocol for the synthesis of <i>pulvinones,</i> and naturally occurring <i>Aspulvinone E</i>, molecules of medicinal interest. Synthetic Communications, 2022, 52, 117-128.	1.1	2
346	Future of Biotransformation Science in the Pharmaceutical Industry. Drug Metabolism and Disposition, 2022, 50, 258-267.	1.7	8
347	In-line formation and identification of toxic reductive metabolites of aristolochic acid using electrochemistry mass spectrometry coupling. Analytical and Bioanalytical Chemistry, 2022, 414, 2363-2370.	1.9	1
348	Tandem Mass Spectrometry Molecular Networking as a Powerful and Efficient Tool for Drug Metabolism Studies. Analytical Chemistry, 2022, 94, 1456-1464.	3.2	17
349	Conventional and Recent Trends of Scaffolds Fabrication: A Superior Mode for Tissue Engineering. Pharmaceutics, 2022, 14, 306.	2.0	37
350	B-nor-methylene Colchicinoid PT-100 Selectively Induces Apoptosis in Multidrug-Resistant Human Cancer Cells via an Intrinsic Pathway in a Caspase-Independent Manner. ACS Omega, 2022, 7, 2591-2603.	1.6	6
351	Proteomic analysis suggests that monoterpenes in lemongrass disrupt Ca<sup>2+</sup> homeostasis in <i>Haemaphysalis longicornis</i> leading to mitochondrial depolarization and cytotoxicity. Proteomics, 2022, 22, e2100156.	1.3	1
352	Interactions of selected cardiovascular active natural compounds with CXCR4 and CXCR7 receptors: a molecular docking, molecular dynamics, and pharmacokinetic/toxicity prediction study. BMC Complementary Medicine and Therapies, 2022, 22, 35.	1.2	18
353	Drug Biotransformation Modeling on Maldi Target Using Multiwell Photocatalytic Microreactor Device. SSRN Electronic Journal, 0, , .	0.4	0
354	Determination of Daphnetin and its 8-O-Methylated Metabolite in Rat Plasma by UFLC-MS/MS: Application to a Pharmacokinetic Study. Chromatographia, 2022, 85, 333-341.	0.7	2
355	Diminishing GSH-Adduct Formation of Tricyclic Diazepine-based Mutant IDH1 Inhibitors. ACS Medicinal Chemistry Letters, 2022, 13, 734-741.	1.3	1
356	Multiwell photocatalytic microreactor device integrating drug biotransformation modeling and sample preparation on a MALDI target. Microchemical Journal, 2022, 178, 107362.	2.3	4
357	Scientific Opinion of the Scientific Panel on Plant Protection Products and their Residues (PPR Panel) on testing and interpretation of comparative in vitro metabolism studies. EFSA Journal, 2021, 19, e06970.	0.9	6

#	ARTICLE	IF	CITATIONS
358	The Ascension of Targeted Covalent Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 5886-5901.	2.9	55
360	Covalent Protein Modification: An Unignorable Factor for Bisphenol A-Induced Hepatotoxicity. <i>Environmental Science &amp; Technology</i> , 2022, 56, 9536-9545.	4.6	9
361	Design and Synthesis of Novel Bis-Imidazolyl Phenyl Butadiyne Derivatives as HCV NS5A Inhibitors. <i>Pharmaceuticals</i> , 2022, 15, 632.	1.7	2
362	Mechanism-driven modeling of chemical hepatotoxicity using structural alerts and an in vitro screening assay. <i>Journal of Hazardous Materials</i> , 2022, 436, 129193.	6.5	18
363	Distal kinetic deuterium isotope effect: Phenyl ring deuteration attenuates N-demethylation of Lu AF35700. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 72, 128879.	1.0	2
364	Modeling drug-induced liver injury: current status and future prospects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 555-573.	1.5	8
365	Covalent Binding Mechanism of Furmonertinib and Osimertinib With Human Serum Albumin. <i>Drug Metabolism and Disposition</i> , 2023, 51, 8-16.	1.7	3
366	The in vitro/in vivo metabolic pathways analysis of lobetyol, lobetyolin, and lobetyolinin, three polyacetylenes from <i>Codonopsis Radix</i> , by UHPLC-Q/TOF-MS and UHPLC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2023, 223, 115140.	1.4	2
367	Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with $\hat{\iota}$ -Substituent Electrophiles Targeting Cysteine. <i>Journal of Chemical Information and Modeling</i> , 2023, 63, 493-506.	2.5	0
368	Assessment of the Xenobiotics Toxicity Taking into Account Their Metabolism. <i>Computational Methods in Engineering &amp; the Sciences</i> , 2023, , 21-51.	0.3	0
369	A pH-Activatable Prodrug and Metal Prodrug Conjugate of Gossypol: Synthesis, Emergent Photophysical, Nanoscopic, Computational, and in vitro Cellular Studies. <i>Chemistry - A European Journal</i> , 2023, 29, .	1.7	0
370	The Promises of Proteomics and Metabolomics for Unravelling the Mechanism and Side Effect Landscape of Beta-Adrenoceptor Antagonists in Cardiovascular Therapeutics. <i>OMICS A Journal of Integrative Biology</i> , 2023, 27, 87-92.	1.0	1
371	<i>Drug Metabolism</i> . , 2023, , 265-297.		0